Outlook Therapeutics, Inc.
Moat Score — Outlook Therapeutics, Inc.
Total Moat Score
6 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | LYTENAVA is the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD, a regulatory position Outlook expects to protect with roughly 12 years of BPCIA reference-product exclusivity. The underlying molecule itself is old and not patent-protected, so the real asset is the approved label and clinical data package, which took Outlook over a decade and two Complete Response Letters to secure, showing genuine (if not insurmountable) difficulty to replicate. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Outlook has no manufacturing or scale cost advantage; it relies on single-source third parties (FujiFilm Diosynth, PCI San Diego) for drug substance and fill-finish. Its core competitive challenge is actually a cost disadvantage versus the off-label compounded Avastin that dominates first-line wet AMD treatment today, which is far cheaper to produce and dispense than an FDA-approved biologic. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | Management's explicit strategy is to price LYTENAVA below approved biosimilars and branded anti-VEGF drugs (Eylea, Vabysmo) but above off-label compounded bevacizumab in order to win volume, which is a market-penetration pricing stance rather than evidence of pricing power. With well-capitalized incumbents and biosimilars also competing on price, Outlook has limited ability to raise prices without ceding share back to cheaper alternatives. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | LYTENAVA is a conventional injectable biologic sold through standard pharmaceutical distribution and physician relationships; there is no mechanism by which additional patients or prescribers make the product more valuable to other users, so no network effect exists. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Retina specialists routinely switch patients among anti-VEGF agents (Eylea, Vabysmo, Lucentis, compounded bevacizumab) based on clinical response, so there is little structural lock-in once a patient starts on a given drug. Some modest friction exists around formulary/HCPCS coding and practice-level purchasing habits, but it is not a durable barrier to switching. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | The global anti-VEGF retina market (roughly $16 billion) comfortably supports multiple large, profitable competitors (Regeneron, Roche/Genentech, Novartis, Amgen) plus numerous biosimilars and the off-label compounding channel, so there is no efficient-scale dynamic protecting Outlook from new entrants or incumbents expanding further into its niche. |